Alkeon Capital Management LLC Biocryst Pharmaceuticals Inc Transaction History

Alkeon Capital Management LLC

$58.2 Billion
Q3 2024

A detailed history of Alkeon Capital Management LLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Alkeon Capital Management LLC holds 7,093,822 shares of BCRX stock, worth $53.9 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares

7,093,822

Previous 7,099,484 0.08%

Holding current value

$53.9 Million

Previous $43.9 Million 22.88%

% of portfolio

0.09%

Previous 0.07%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$6.41 - $8.69 $36,293 - $49,202	-5,662 Reduced 0.08%	7,093,822 $53.9 Million
Q2 2024 Aug 13, 2024	BUY	$4.13 - $6.79 $12.4 Million - $20.4 Million	3,000,000 Added 73.18%	7,099,484 $43.9 Million
Q1 2024 May 14, 2024	BUY	$4.89 - $7.65 $11.9 Million - $18.6 Million	2,430,000 Added 145.55%	4,099,484 $20.8 Million
Q4 2023 Feb 13, 2024	SELL	$4.98 - $6.77 $14,088 - $19,152	-2,829 Reduced 0.17%	1,669,484 $10 Million
Q2 2023 Aug 11, 2023	BUY	$6.96 - $8.81 $2.81 Million - $3.55 Million	403,461 Added 31.8%	1,672,313 $11.8 Million
Q1 2023 May 12, 2023	SELL	$7.94 - $11.84 $1.72 Million - $2.57 Million	-216,965 Reduced 14.6%	1,268,852 $10.6 Million
Q4 2022 Feb 13, 2023	BUY	$10.5 - $14.2 $215,586 - $291,554	20,532 Added 1.4%	1,485,817 $17.1 Million
Q3 2022 Nov 10, 2022	BUY	$10.79 - $14.81 $3.2 Million - $4.4 Million	296,940 Added 25.42%	1,465,285 $18.5 Million
Q2 2022 Aug 15, 2022	SELL	$7.89 - $17.88 $153,855 - $348,660	-19,500 Reduced 1.64%	1,168,345 $12.4 Million
Q1 2022 May 16, 2022	BUY	$11.56 - $19.76 $13.7 Million - $23.5 Million	1,187,845 New	1,187,845 $19.3 Million

Others Institutions Holding BCRX

# of Institutions

279

Shares Held

172M

Call Options Held

625K

Put Options Held

739K

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.41B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alkeon Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alkeon Capital Management LLC with notifications on news.

Account

Alkeon Capital Management LLC Biocryst Pharmaceuticals Inc Transaction History